辉瑞-BioNTech COVID-19 疫苗接种对血小板的长期影响。
Long-term effects of Pfizer-BioNTech COVID-19 vaccinations on platelets.
机构信息
Department of Chemistry, The University of Tokyo, Tokyo, Japan.
Department of Clinical Laboratory, The University of Tokyo Hospital, Tokyo, Japan.
出版信息
Cytometry A. 2023 Feb;103(2):162-167. doi: 10.1002/cyto.a.24677. Epub 2022 Aug 8.
Abstract
There is a global concern about the safety of COVID-19 vaccines associated with platelet function. However, their long-term effects on overall platelet activity remain poorly understood. Here we address this problem by image-based single-cell profiling and temporal monitoring of circulating platelet aggregates in the blood of healthy human subjects, before and after they received multiple Pfizer-BioNTech (BNT162b2) vaccine doses over a time span of nearly 1 year. Results show no significant or persisting platelet aggregation trends following the vaccine doses, indicating that any effects of vaccinations on platelet turnover, platelet activation, platelet aggregation, and platelet-leukocyte interaction was insignificant.
摘要
人们普遍关注与血小板功能相关的 COVID-19 疫苗的安全性。然而，它们对整体血小板活性的长期影响仍知之甚少。在这里，我们通过基于图像的单细胞分析，并在健康人体血液中对循环血小板聚集体进行时间监测，解决了这个问题，这些人在将近 1 年的时间里接受了多次辉瑞-生物科技（BNT162b2）疫苗接种。结果表明，疫苗接种后没有明显或持续的血小板聚集趋势，这表明接种疫苗对血小板更新、血小板激活、血小板聚集和血小板-白细胞相互作用没有显著影响。
相似文献
1
Long-term effects of Pfizer-BioNTech COVID-19 vaccinations on platelets.辉瑞-BioNTech COVID-19 疫苗接种对血小板的长期影响。
Cytometry A. 2023 Feb;103(2):162-167. doi: 10.1002/cyto.a.24677. Epub 2022 Aug 8.
2
Side effects of Pfizer/BioNTech (BNT162b2) COVID-19 vaccine reported by the Birzeit University community.贝鲁特大学社区报告的辉瑞/生物新技术（BNT162b2） COVID-19 疫苗的副作用。
BMC Infect Dis. 2023 Jan 5;23(1):5. doi: 10.1186/s12879-022-07974-3.
3
Distinct platelet crosstalk with adaptive and innate immune cells after adenoviral and mRNA vaccination against SARS-CoV-2.腺病毒和 mRNA 疫苗接种 SARS-CoV-2 后，血小板与适应性和固有免疫细胞的独特串扰。
J Thromb Haemost. 2023 Jun;21(6):1636-1649. doi: 10.1016/j.jtha.2023.03.003. Epub 2023 Mar 12.
4
Exploring the adverse events of Oxford-AstraZeneca, Pfizer-BioNTech, Moderna, and Johnson and Johnson COVID-19 vaccination on Guillain-Barré Syndrome.探讨牛津-阿斯利康、辉瑞-BioNTech、莫德纳和强生 COVID-19 疫苗接种对吉兰-巴雷综合征的不良事件。
Sci Rep. 2024 Aug 13;14(1):18767. doi: 10.1038/s41598-024-66999-7.
5
Evaluation of hematological parameters and thrombocytopenia following Pfizer-BioNTech (BNT162b2) SARS-CoV-2 vaccination.辉瑞-生物科技（BNT162b2）SARS-CoV-2 疫苗接种后对血液学参数和血小板减少症的评估。
Saudi Med J. 2022 Jun;43(6):567-571. doi: 10.15537/smj.2022.43.6.20220135.
6
Epidemiology of Myocarditis and Pericarditis Following mRNA Vaccination by Vaccine Product, Schedule, and Interdose Interval Among Adolescents and Adults in Ontario, Canada.加拿大安大略省青少年和成年人中，基于疫苗产品、接种程序和剂间间隔的 mRNA 疫苗接种后心肌炎和心包炎的流行病学。
JAMA Netw Open. 2022 Jun 1;5(6):e2218505. doi: 10.1001/jamanetworkopen.2022.18505.
7
Vaccine-Associated Uveitis after COVID-19 Vaccination: Vaccine Adverse Event Reporting System Database Analysis.接种新冠疫苗后出现的葡萄膜炎：疫苗不良事件报告系统数据库分析。
Ophthalmology. 2023 Feb;130(2):179-186. doi: 10.1016/j.ophtha.2022.08.027. Epub 2022 Aug 31.
8
Myocarditis and/or pericarditis risk after mRNA COVID-19 vaccination: A Canadian head to head comparison of BNT162b2 and mRNA-1273 vaccines.mRNA COVID-19 疫苗接种后的心肌炎和/或心包炎风险：BNT162b2 和 mRNA-1273 疫苗的加拿大头对头比较。
Vaccine. 2022 Jul 30;40(32):4663-4671. doi: 10.1016/j.vaccine.2022.05.048. Epub 2022 May 25.
9
Safety Monitoring of Pfizer-BioNTech COVID-19 Vaccine Booster Doses Among Children Aged 5-11 Years - United States, May 17-July 31, 2022.辉瑞-BioNTech COVID-19 疫苗加强针在 5-11 岁儿童中的安全性监测 - 美国，2022 年 5 月 17 日至 7 月 31 日。
MMWR Morb Mortal Wkly Rep. 2022 Aug 19;71(33):1047-1051. doi: 10.15585/mmwr.mm7133a3.
10
Incidence of Guillain-Barré Syndrome After COVID-19 Vaccination in the Vaccine Safety Datalink.疫苗安全数据链接中 COVID-19 疫苗接种后吉兰-巴雷综合征的发生率。
JAMA Netw Open. 2022 Apr 1;5(4):e228879. doi: 10.1001/jamanetworkopen.2022.8879.
引用本文的文献
1
Multisystem Endothelial Inflammation: A Key Driver of Adverse Events Following mRNA-Containing COVID-19 Vaccines.多系统内皮炎症：含mRNA的新冠疫苗接种后不良事件的关键驱动因素
Vaccines (Basel). 2025 Aug 12;13(8):855. doi: 10.3390/vaccines13080855.
2
Increased platelet-neutrophil aggregate ratio after severe acute respiratory syndrome coronavirus 2 vaccination and severe infection.严重急性呼吸综合征冠状病毒2疫苗接种和严重感染后血小板-中性粒细胞聚集率升高。
Sci Prog. 2025 Jul-Sep;108(3):368504251352079. doi: 10.1177/00368504251352079. Epub 2025 Jul 17.
3
Direct evaluation of antiplatelet therapy in coronary artery disease by comprehensive image-based profiling of circulating platelets.通过基于图像的循环血小板综合分析直接评估冠状动脉疾病中的抗血小板治疗。
Nat Commun. 2025 May 15;16(1):4386. doi: 10.1038/s41467-025-59664-8.
4
People having hematological disorders and hypercoagulability state need extra precautions because of the increased risk of thrombosis after COVID-19 vaccination.患有血液系统疾病和高凝状态的人由于在接种新冠疫苗后发生血栓形成的风险增加，需要格外注意。
Front Med (Lausanne). 2023 Feb 14;9:1082611. doi: 10.3389/fmed.2022.1082611. eCollection 2022.
5
Real-time intelligent classification of COVID-19 and thrombosis via massive image-based analysis of platelet aggregates.通过基于海量图像的血小板聚集物分析实现 COVID-19 和血栓的实时智能分类。
Cytometry A. 2023 Jun;103(6):492-499. doi: 10.1002/cyto.a.24721. Epub 2023 Feb 21.
6
Head-to-head comparison of four COVID-19 vaccines on platelet activation, coagulation and inflammation. The TREASURE study.四种 COVID-19 疫苗对血小板活化、凝血和炎症的头对头比较。TREASURE 研究。
Thromb Res. 2023 Mar;223:24-33. doi: 10.1016/j.thromres.2023.01.015. Epub 2023 Jan 18.
7
Thrombotic outcomes in patients in a large clinical enterprise following COVID-19 vaccination.接种 COVID-19 疫苗后大型临床企业中的患者的血栓形成结局。
J Thromb Thrombolysis. 2023 Apr;55(3):426-431. doi: 10.1007/s11239-022-02764-9. Epub 2023 Jan 18.
8
Pathophysiological mechanisms of thrombosis in acute and long COVID-19.急性 COVID-19 和长新冠中的血栓形成的病理生理学机制。
Front Immunol. 2022 Nov 16;13:992384. doi: 10.3389/fimmu.2022.992384. eCollection 2022.
本文引用的文献
1
Anti-severe acute respiratory syndrome coronavirus-2 adenoviral-vector vaccines trigger subclinical antiplatelet autoimmunity and increase of soluble platelet activation markers.抗严重急性呼吸综合征冠状病毒 2 腺病毒载体疫苗引发亚临床抗血小板自身免疫和可溶性血小板活化标志物增加。
Br J Haematol. 2022 Jul;198(2):257-266. doi: 10.1111/bjh.18245. Epub 2022 May 16.
2
Assessing Clinically Meaningful Hypercoagulability after COVID-19 Vaccination: A Longitudinal Study.评估 COVID-19 疫苗接种后的临床显著高凝状态：一项纵向研究。
Thromb Haemost. 2022 Aug;122(8):1352-1360. doi: 10.1055/a-1788-5206. Epub 2022 Mar 4.
3
Platelet and immune signature associated with a rapid response to the BNT162b2 mRNA COVID-19 vaccine.与对 BNT162b2 mRNA COVID-19 疫苗快速反应相关的血小板和免疫特征。
J Thromb Haemost. 2022 Apr;20(4):961-974. doi: 10.1111/jth.15648. Epub 2022 Jan 26.
4
Massive image-based single-cell profiling reveals high levels of circulating platelet aggregates in patients with COVID-19.基于海量图像的单细胞分析揭示 COVID-19 患者循环血小板聚集物水平较高。
Nat Commun. 2021 Dec 9;12(1):7135. doi: 10.1038/s41467-021-27378-2.
5
Surveillance for Adverse Events After COVID-19 mRNA Vaccination.COVID-19 mRNA 疫苗接种后不良事件的监测。
JAMA. 2021 Oct 12;326(14):1390-1399. doi: 10.1001/jama.2021.15072.
6
mRNA vaccine: a potential therapeutic strategy.mRNA 疫苗：一种有潜力的治疗策略。
Mol Cancer. 2021 Feb 16;20(1):33. doi: 10.1186/s12943-021-01311-z.
7
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.BNT162b2 mRNA 新冠病毒疫苗的安全性和有效性。
N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.
8
Immunological considerations for COVID-19 vaccine strategies.针对 COVID-19 疫苗策略的免疫学考虑。
Nat Rev Immunol. 2020 Oct;20(10):615-632. doi: 10.1038/s41577-020-00434-6. Epub 2020 Sep 4.
9
Intelligent classification of platelet aggregates by agonist type.根据激动剂类型对血小板聚集物进行智能分类。
Elife. 2020 May 12;9:e52938. doi: 10.7554/eLife.52938.
10
Patrolling the vascular borders: platelets in immunity to infection and cancer.巡逻血管边界：血小板在抗感染和抗癌中的作用。
Nat Rev Immunol. 2019 Dec;19(12):747-760. doi: 10.1038/s41577-019-0202-z. Epub 2019 Aug 13.
Zotero 插件